Compartir
array:22 [ "pii" => "S0214916824000780" "issn" => "02149168" "doi" => "10.1016/j.arteri.2024.08.002" "estado" => "S200" "fechaPublicacion" => "2024-09-10" "aid" => "732" "copyright" => "Sociedad Española de Arteriosclerosis" "copyrightAnyo" => "2024" "documento" => "simple-article" "crossmark" => 0 "subdocumento" => "cor" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "itemSiguiente" => array:17 [ "pii" => "S0214916824000792" "issn" => "02149168" "doi" => "10.1016/j.arteri.2024.08.003" "estado" => "S200" "fechaPublicacion" => "2024-09-13" "aid" => "733" "copyright" => "The Authors" "documento" => "article" "crossmark" => 0 "subdocumento" => "sco" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Methodological notes</span>" "titulo" => "Novel protocol for the transcriptomic analysis of endothelial extracellular vesicles in atherosclerosis" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Nuevo protocolo para el análisis transcriptómico de las vesículas extracelulares endoteliales en aterosclerosis" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0020" "etiqueta" => "Figure 4" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr4.jpeg" "Alto" => 3309 "Ancho" => 3350 "Tamanyo" => 1097258 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Differential expression analysis of EEVs in control (G1), subclinical atherosclerosis (G2) and PAD patients (G3). (A) Volcano plot showing the differentially expressed genes (DEG) of the contrasts performed by LimmaVoom for G2 vs G1. In green those with a fold-change (log2FC) lower than −1.5 and in red the ones with log2FC higher than 1.5 and a <span class="elsevierStyleItalic">p</span>-value <0.05. (B) Gene ontology (GO) analysis for biological processes with the 177 transcripts differentially expressed in G2 vs G1. (C) Volcano plot for the contrasts performed by LimmaVoom for G1 vs G3 to identify DEG. In green those with a log2FC <−1.5 and in red the ones with a log2FC >1.5 and a <span class="elsevierStyleItalic">p</span>-value <0.05. (D) GO analysis for biological processes with the 188 transcripts differentially expressed in G3 vs G1.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Goren Saenz-Pipaon, Ana Cenarro, Jon Zazpe, Miriam Goñi-Oloriz, Esther Martinez-Aguilar, Florencio J.D. Machado, Francesco P. Marchese, Josune Orbe, Natalia López-Andrés, Fernando Civeira, Jose A. Paramo, David Lara-Astiaso, Carmen Roncal" "autores" => array:13 [ 0 => array:2 [ "nombre" => "Goren" "apellidos" => "Saenz-Pipaon" ] 1 => array:2 [ "nombre" => "Ana" "apellidos" => "Cenarro" ] 2 => array:2 [ "nombre" => "Jon" "apellidos" => "Zazpe" ] 3 => array:2 [ "nombre" => "Miriam" "apellidos" => "Goñi-Oloriz" ] 4 => array:2 [ "nombre" => "Esther" "apellidos" => "Martinez-Aguilar" ] 5 => array:2 [ "nombre" => "Florencio J.D." "apellidos" => "Machado" ] 6 => array:2 [ "nombre" => "Francesco P." "apellidos" => "Marchese" ] 7 => array:2 [ "nombre" => "Josune" "apellidos" => "Orbe" ] 8 => array:2 [ "nombre" => "Natalia" "apellidos" => "López-Andrés" ] 9 => array:2 [ "nombre" => "Fernando" "apellidos" => "Civeira" ] 10 => array:2 [ "nombre" => "Jose A." "apellidos" => "Paramo" ] 11 => array:2 [ "nombre" => "David" "apellidos" => "Lara-Astiaso" ] 12 => array:2 [ "nombre" => "Carmen" "apellidos" => "Roncal" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0214916824000792?idApp=UINPBA00004N" "url" => "/02149168/unassign/S0214916824000792/v1_202409130424/en/main.assets" ] "itemAnterior" => array:17 [ "pii" => "S0214916824000354" "issn" => "02149168" "doi" => "10.1016/j.arteri.2024.03.005" "estado" => "S200" "fechaPublicacion" => "2024-05-03" "aid" => "717" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "es" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original</span>" "titulo" => "Caracterización clínica y detección de arteriosclerosis subclínica en sujetos con hiperalfalipoproteinemia extrema" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Clinical characterization and detection of subclinical atherosclerosis in subjects with extreme hyperalphalipoproteinemia" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Javier Espíldora-Hernández, Tania Díaz-Antonio, Jesús Olmedo-Llanes, Jesús Zarzuela León, José Rioja, Pedro Valdivielso, Miguel Ángel Sánchez-Chaparro, María José Ariza" "autores" => array:8 [ 0 => array:2 [ "nombre" => "Javier" "apellidos" => "Espíldora-Hernández" ] 1 => array:2 [ "nombre" => "Tania" "apellidos" => "Díaz-Antonio" ] 2 => array:2 [ "nombre" => "Jesús" "apellidos" => "Olmedo-Llanes" ] 3 => array:2 [ "nombre" => "Jesús" "apellidos" => "Zarzuela León" ] 4 => array:2 [ "nombre" => "José" "apellidos" => "Rioja" ] 5 => array:2 [ "nombre" => "Pedro" "apellidos" => "Valdivielso" ] 6 => array:2 [ "nombre" => "Miguel Ángel" "apellidos" => "Sánchez-Chaparro" ] 7 => array:2 [ "nombre" => "María José" "apellidos" => "Ariza" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2529912324000640" "doi" => "10.1016/j.artere.2024.10.001" "estado" => "S200" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529912324000640?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0214916824000354?idApp=UINPBA00004N" "url" => "/02149168/unassign/S0214916824000354/v1_202405030434/es/main.assets" ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>" "titulo" => "When “old” lipid lowering therapies not should be discontinued" "tieneTextoCompleto" => true "saludo" => "Dear Editor," "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Francesco Sbrana, Beatrice Dal Pino" "autores" => array:2 [ 0 => array:4 [ "nombre" => "Francesco" "apellidos" => "Sbrana" "email" => array:1 [ 0 => "Francesco.sbrana@ftgm.it" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:2 [ "nombre" => "Beatrice" "apellidos" => "Dal Pino" ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Lipoapheresis Unit and Reference Center for Inherited Dyslipidemias, Fondazione Toscana Gabriele Monasterio, Pisa, Italy" "identificador" => "aff0005" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Cuándo no se deben suspender las terapias hipolipemiantes «antiguas»" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">We read with interest Vila À et al. titled “<span class="elsevierStyleItalic">Observational study of patients from a Lipid Unit on lipid-modifying therapy for primary and secondary prevention: ULFI Study</span>”<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">1</span></a> highlighting that factors associated with therapeutic lipid lowering success were the presence of arteriosclerotic cardiovascular disease, the intensity of lipid-lowering treatment (LLT), diabetes mellitus, and low to moderate alcohol consumption but we have to consider that low adherence to LLT is one of the main reasons beyond the failure in achieving the recommended lipid targets in several patients. The ULFI study is in agree with the SANTORINI study<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">2</span></a> who reported that a considerable proportion of subjects at high and very high cardiovascular risk fail to reach the LDL-cholesterol goals established by the guidelines (<70 and <55<span class="elsevierStyleHsp" style=""></span>mg/dL, respectively) although prescribing attitudes changed over time, with a rising, trend toward more aggressive LLT interventions. Recently, ESC indications<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">3</span></a> highlighting the importance of periodic reassessment of chronic cardiovascular therapy especially after a lengthy period of treatment. However, between the several discussed cardiovascular medications, some further considerations need to be made regarding the LLT:<ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005"><span class="elsevierStyleLabel">i)</span><p id="par0010" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleBold">Niacin</span> treatment, although able to increase HDL cholesterol levels especially in familial hypoalphalipoproteinemia, increase the frequency of serious adverse events with an unfavorable risk/benefit ration and the <span class="elsevierStyleBold">fish oil supplementation</span> (<1<span class="elsevierStyleHsp" style=""></span>g/day) has an irrelevant therapeutic effect although a very high daily dose is not recommended, especially in patients with heart disease, due to the risk of atrial fibrillation.<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">4</span></a></p></li><li class="elsevierStyleListItem" id="lsti0010"><span class="elsevierStyleLabel">ii)</span><p id="par0015" class="elsevierStylePara elsevierViewall">Statin-associated muscle symptoms (SAMS) are a major determinant of poor treatment adherence and/or statin discontinuation but this condition can benefit from <span class="elsevierStyleBold">coenzyme Q10 supplementation</span> especially when CPK values are high before start statin therapy.<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">5</span></a> Moreover, SAMS could be the opportunity to identify, through <span class="elsevierStyleBold">vitamin D</span> dosage, states of vitamin deficiency in order to start specific therapy.</p></li><li class="elsevierStyleListItem" id="lsti0015"><span class="elsevierStyleLabel">iii)</span><p id="par0020" class="elsevierStylePara elsevierViewall">Among patients with atherosclerotic cardiovascular disease (ASCVD), hypertriglyceridemia is common, and is associated with higher ASCVD risk across a range of TG.<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">6</span></a> Lowering triglycerides with <span class="elsevierStyleBold">fibrates</span> reduces the risk of cardiovascular events by the same amount as LDL-C-lowering therapies when measured per unit change of non-HDL-C. Combinations of statins with gemfibrozil may enhance the risk for myopathy but this risk seems to be small using fenofibrate and routinary monitoring CPK.<a class="elsevierStyleCrossRef" href="#bib0080"><span class="elsevierStyleSup">7</span></a></p></li><li class="elsevierStyleListItem" id="lsti0020"><span class="elsevierStyleLabel">iv)</span><p id="par0025" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleBold">Simvastatin</span> has a good safety profile, especially in chronic kidney disease,<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">8</span></a> and adding ezetimibe allowed an LDL-cholesterol reduction great then 50% in a large number of high cardiovascular risk subjects.</p></li></ul></p><p id="par0030" class="elsevierStylePara elsevierViewall">All strategies, according to the operative international lipid expert panel indication and with protocol to valorized the therapeutic adherence,<a class="elsevierStyleCrossRefs" href="#bib0050"><span class="elsevierStyleSup">1,9</span></a> have a role to improve the LLT effectiveness don’t forget, in the era of “new” lipid-lowering drugs, cornerstone data regarding “old” LLT.</p><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0005">Funding sources</span><p id="par0035" class="elsevierStylePara elsevierViewall">No financial support was received.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Author approval</span><p id="par0040" class="elsevierStylePara elsevierViewall">All authors have seen and approved the study submitted.</p><p id="par0045" class="elsevierStylePara elsevierViewall">No part of the submitted work has been published or is under consideration for publication elsewhere.</p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Authors’ contribution</span><p id="par0050" class="elsevierStylePara elsevierViewall">FS and BDP: contributed to conception or design, drafted and critically revised the manuscript. All authors read and approved the final version of the manuscript.</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">Notes</span><p id="par0055" class="elsevierStylePara elsevierViewall">Data have not been presented at any congress.</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Consent for publication</span><p id="par0060" class="elsevierStylePara elsevierViewall">The patient signed the informed consent from form for anonymous medical data usage in our paper.</p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Conflict of interest</span><p id="par0065" class="elsevierStylePara elsevierViewall">No conflict of interest for each author.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:8 [ 0 => array:2 [ "identificador" => "sec0005" "titulo" => "Funding sources" ] 1 => array:2 [ "identificador" => "sec0010" "titulo" => "Author approval" ] 2 => array:2 [ "identificador" => "sec0015" "titulo" => "Authors’ contribution" ] 3 => array:2 [ "identificador" => "sec0020" "titulo" => "Notes" ] 4 => array:2 [ "identificador" => "sec0025" "titulo" => "Consent for publication" ] 5 => array:2 [ "identificador" => "sec0030" "titulo" => "Conflict of interest" ] 6 => array:2 [ "identificador" => "xack771916" "titulo" => "Acknowledgements" ] 7 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:9 [ 0 => array:3 [ "identificador" => "bib0050" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Observational study of patients from a Lipid Unit on lipid-modifying therapy for primary and secondary prevention: ULFI study" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "À. Vila" 1 => "E. Pons" 2 => "P.T. García" 3 => "D. Vidal" 4 => "S. López" 5 => "A. Grau" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.arteri.2023.06.002" "Revista" => array:7 [ "tituloSerie" => "Clin Investig Arterioscler" "fecha" => "2023" "volumen" => "35" "paginaInicial" => "272" "paginaFinal" => "279" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/37479646" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S1053249822020745" "estado" => "S300" "issn" => "10532498" ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0055" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Evaluation of contemporary treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe—methodology and rationale for the multinational observational SANTORINI study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "K.K. Ray" 1 => "I. Haq" 2 => "A. Bilitou" 3 => "C. Aguiar" 4 => "M. Arca" 5 => "D.L. Connolly" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Atheroscler Plus" "fecha" => "2021" "volumen" => "13" "paginaInicial" => "24" "paginaFinal" => "30" "itemHostRev" => array:3 [ "pii" => "S2213177920300846" "estado" => "S300" "issn" => "22131779" ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0060" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "When cardiovascular medicines should be discontinued" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "K.A. Krychtiuk" 1 => "B.J. Gersh" 2 => "J.B. Washam" 3 => "C.B. Granger" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/eurheartj/ehae302" "Revista" => array:6 [ "tituloSerie" => "Eur Heart J" "fecha" => "2024" "volumen" => "45" "paginaInicial" => "2039" "paginaFinal" => "2051" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/38838241" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0065" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Omega-3 fatty acids supplementation and risk of atrial fibrillation: an updated meta-analysis of randomized controlled trials" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Lombardi" 1 => "S. Carbone" 2 => "M.G. Del Buono" 3 => "J.G. Chiabrando" 4 => "G.M. Vescovo" 5 => "M. Camilli" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/ehjcvp/pvab008" "Revista" => array:6 [ "tituloSerie" => "Eur Heart J Cardiovasc Pharmacother" "fecha" => "2021" "volumen" => "7" "paginaInicial" => "e69" "paginaFinal" => "e70" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33910233" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0070" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effect of coenzyme Q on serum levels of creatine phosphokinase in preclinical muscular dystrophy" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "K. A. Folkers" 1 => "R. Nakamura" 2 => "G.P. Littarru" 3 => "H. Zellweger" 4 => "J.B. Brunkhorst" 5 => "C.W. Williams Jr." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1073/pnas.71.5.2098" "Revista" => array:6 [ "tituloSerie" => "Proc Natl Acad Sci USA" "fecha" => "1974" "volumen" => "71" "paginaInicial" => "2098" "paginaFinal" => "2102" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/4525474" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0075" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P.R. Lawler" 1 => "G. Kotrri" 2 => "M. Koh" 3 => "S.G. Goodman" 4 => "M.E. Farkouh" 5 => "D.S. Lee" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/eurheartj/ehz767" "Revista" => array:6 [ "tituloSerie" => "Eur Heart J" "fecha" => "2020" "volumen" => "41" "paginaInicial" => "86" "paginaFinal" => "94" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31733058" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0080" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "F. Mach" 1 => "C. Baigent" 2 => "A.L. Catapano" 3 => "K.C. Koskinas" 4 => "M. Casula" 5 => "L. Badimon" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/eurheartj/ehz455" "Revista" => array:6 [ "tituloSerie" => "Eur Heart J" "fecha" => "2020" "volumen" => "41" "paginaInicial" => "111" "paginaFinal" => "188" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31504418" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0085" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9438 patients with chronic kidney disease" "autores" => array:1 [ 0 => array:2 [ "colaboracion" => "Sharp Collaborative Group" "etal" => false ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ "tituloSerie" => "Am Heart J" "fecha" => "2010" "volumen" => "160" ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0090" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Therapeutic adherence in hyperlipidemia: when one size doesn’t fit all" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "B. Dal Pino" 1 => "F. Sbrana" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ejim.2023.03.003" "Revista" => array:6 [ "tituloSerie" => "Eur J Intern Med" "fecha" => "2023" "volumen" => "112" "paginaInicial" => "143" "paginaFinal" => "145" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/36894410" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] "agradecimientos" => array:1 [ 0 => array:4 [ "identificador" => "xack771916" "titulo" => "Acknowledgements" "texto" => "<p id="par0070" class="elsevierStylePara elsevierViewall">None.</p>" "vista" => "all" ] ] ] "idiomaDefecto" => "en" "url" => "/02149168/unassign/S0214916824000780/v1_202409100415/en/main.assets" "Apartado" => null "PDF" => "https://static.elsevier.es/multimedia/02149168/unassign/S0214916824000780/v1_202409100415/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0214916824000780?idApp=UINPBA00004N" ]
